Johnson & Johnson Approaches Actelion About Potential Deal
26 November 2016 - 4:12AM
Dow Jones News
By Austen Hufford
Biopharmaceutical company Actelion Ltd. said Friday that it had
been approached by Johnson & Johnson about a possible deal.
Shares rose 16% to 182.40 Swiss francs on the SIX Swiss
Exchange.
J&J didn't immediately respond to a request for comment.
Last year, Switzerland-based Actelion reported revenue of 2.05
billion francs ($2.02 billion) and a profit of 551.9 million
francs.
Actelion, which had its initial public offering at the turn of
the century, focuses on drugs for pulmonary arterial hypertension,
a type of high blood pressure that affects arteries in the lungs
and in the heart.
Bloomberg reported Thursday that J&J had made an initial bid
for the specialty drug company.
Shares of J&J rose 0.7% to $113.88 in morning trading in the
U.S.
Write to Austen Hufford at austen.hufford@wsj.com
(END) Dow Jones Newswires
November 25, 2016 11:57 ET (16:57 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2024 to May 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From May 2023 to May 2024